Mr. Fromen became the Chief Executive Officer of biomodal, formerly Cambridge Epigenetix, in 2022. Before that Mr. Fromen worked at PacBio, where he served as Chief Commercial Officer. Prior to PacBio, Mr. Fromen worked at Illumina, where he held numerous leadership positions across the finance and commercial organisations including investor relations, product marketing, market development, and enterprise sales.
He built the Company’s first investor relations and market development functions and had a leading role in launching the Company’s HiSeq X Ten Sequencing System, which delivered the first $1000 human whole genome.
While serving as the company’s Global Vice President of Population Genomics and Precision Health, Mr. Fromen oversaw Illumina’s partnership with Genomics England and the National Health System. Mr. Fromen received a BA degree from Kenyon College and MBA from Arizona State University.
Peter Fromen
Chief Executive Officer
